Clinical and nutritional effectiveness of a nutritional protocol with oligomeric enteral nutrition in patients with oncology treatment-related diarrhea by Sanz-Paris, A. et al.
nutrients
Article
Clinical and Nutritional Effectiveness of a Nutritional
Protocol with Oligomeric Enteral Nutrition in
Patients with Oncology Treatment-Related Diarrhea
Alejandro Sanz-Paris 1,2,*, Javier Martinez-Trufero 3 , Julio Lambea-Sorrosal 4,
Fernando Calvo-Gracia 5 and Raimon Milà-Villarroel 6
1 Department of Endocrinology and Nutrition, Miguel Servet Hospital, 50009 Zaragoza, Spain
2 Instituto de Investigación Sanitaria Aragón (IIS Aragon), 50009 Zaragoza, Spain
3 Department of Oncology, Miguel Servet Hospital, 50009 Zaragoza, Spain; jmtrufero@seom.org
4 Department of Oncology, University Clinic Hospital, 50009 Zaragoza, Spain; juliolambea@yahoo.es
5 Department of Endocrinology and Nutrition, University Clinic Hospital, 50009 Zaragoza, Spain;
fcalvo@comz.org
6 Group Research on Wellbeing (GRoW), Blanquerna School of Health Sciences–Universitat Ramon Llull,
08025 Barcelona, Spain; raimonmv@blanquerna.url.edu
* Correspondence: asanzp@salud.aragon.es; Tel.: +34-651667352
Received: 16 April 2020; Accepted: 23 May 2020; Published: 25 May 2020


Abstract: (1) Background: Poor nutritional status and diarrhea are common complications in
cancer patients. (2) Methods: This multicenter, observational, prospective study evaluated the
effectiveness of an oligomeric enteral nutrition (OEN) protocol in the improvement of nutritional
status and reduction of diarrhea symptoms. Nutritional status was assessed with the Subjective
Global Assessment (SGA), Body Mass Index (BMI) and albumin levels. Diarrhea was evaluated by
the frequency and consistency of stools (Bristol Stool form scale). (3) Results: After 8 weeks of OEN
protocol, the nutritional status improved in 48.3% of patients, with an increased proportion of patients
at risk of malnourishment (+27.3%) at the expense of a decrease of moderately (−19.9%) and severely
(−7.3%) malnourished patients (p < 0.001). Serum albumin and BMI significantly increased after
8 weeks of OEN treatment (p < 0.005). OEN showed a 71.1% effectiveness in the improvement of stool
consistency. The mean number of stools per day significantly decreased from baseline (4.17 stools/day)
to week 8 (1.42 stools/day; p = 0.0041). The nutritional status significantly improved even in those
patients with persistent diarrhea. (4) Conclusion: The proposed OEN protocol seemed to be effective
in improving the nutritional status, frequency and consistency of stools in patients with oncology
treatment-related diarrhea even in persistent cases.
Keywords: oncology treatment-related diarrhea; nutritional protocol; oligomeric enteral nutrition
1. Introduction
Despite the improvement in patient’s prognosis and life expectancy enabled by cancer therapy,
oncological patients frequently suffer from associated side effects, being gastrointestinal complications
particularly common [1].
Chemotherapy, other systemic treatments, and radiotherapy can induce and exacerbate the
inflammation of the gastrointestinal tract mucosa, resulting in taste changes, nausea, constipation
and diarrhea [2]. Of particular importance is oncology treatment-related diarrhea (OTRD) due to its
effects on hydration and electrolyte balance, which can severely compromise the nutritional status of
patients [3]. The frequency of OTRD ranged from 5 to 74% in randomized clinical trials, becoming a
common cause of hospital admissions and being life-threatening in persistent and severe cases [4].
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Cancer patients are therefore at high risk for malnourishment, with a prevalence that varies
widely with the type and stage of tumor, cancer therapy modality and intensity [5]. Previous studies
showed that poor nutritional status was associated with a higher rate of hospital admissions, increased
hospital length of stay, reduced quality of life and mortality, and lower tolerance to therapy in cancer
patients [6]. All these complications add an extra burden to the negative effects that cancer itself has
for patients and healthcare systems [7].
Since these complications are progressive, early identification and intervention in patients at
risk will minimize the progression towards more severe states that could prevent from continuing
cancer therapy and threaten the life of the patient [7]. However, clinical guidelines mostly focus on the
pharmacological treatment of diarrhea but do not specifically address the required nutritional support
for patients [4–6,8–10]. Depending on the severity and persistence of symptoms, these interventions
can range from dietary counselling and food supplements to medical nutrition therapy [11]. Among the
latter, oral enteral nutrition can be an advantageous alternative to meet the nutritional demands of
patients with OTRD and clinical stability [12].
However, specific guidance on this type of nutritional support is scarce. To address this unmet
need, we recently published a nutritional support algorithm for patients with OTRD using oligomeric
enteral nutrition (OEN) [13]. OEN is a nutritionally complete formula in which peptides (instead of
whole proteins) are the source of nitrogen and fats are mainly provided as medium-chain triglycerides.
This readily digestible source of nutrients increases digestibility, thereby facilitating the absorption of
nutrients, protecting mucosal integrity, and showing low antigenic effect [14]. We developed a stepwise
approach for patients with OTRD that considers the nutritional status (at risk of malnourishment,
moderate or severe malnourishment) and the intestinal function (preserved or impaired) of patients.
Depending on the severity and persistence of symptoms, the OEN protocol is recommended in different
stages of OTRD to improve the nutritional status of patients and prevent diarrhea and dehydration in
the long term [13]. In this study, we present for the first time the impact of this protocol of nutritional
support in a population of patients with cancer and OTRD.
2. Materials and Methods
2.1. Study Design
This multicenter, observational, prospective cohort study was conducted at 15 Spanish centers
with the involvement of Medical Oncology, Radiation Oncology, and Nutrition departments. The study
adhered to the tenets of the Declaration of Helsinki and was approved by the Ethics Committee of
Comunidad Autónoma de Aragón (CEICA, Code CP-CI.PI 15/0319). All participants provided written
informed consent before inclusion in the study.
The nutritional status of patients, stool characteristics, and other clinical variables were collected
before the initiation of nutritional treatment with OEN (baseline) and after 8 weeks. Nutritional support
consisted of Survimed OPD Drink® (Fresenius Kabi, Bad Homburg, Germany), a peptide-based sip
feed with the following composition: hydrolyzed proteins (18.6%, whey proteins), carbohydrates
(56.4%: 30% saccharose and 70% oligosaccharides), and fat content (25%; 51% as medium-chain
triglycerides) at a final caloric density of 1 Kcal/mL (Supplementary Information).
The nutritional protocol comprised the following steps: (1) Assessing the nutritional status of
patients with the Subjective Global Assessment (SGA), and (2) Evaluating the intestinal function of
patients [13] (see Graphical Abstract). Patients received 2 or 3 bottles per day (200 mL/bottle) of OEN
according to their nutritional status and intestinal function.
The OEN protocol was started at the onset of OTRD. Furthermore, patients were recommended to
follow an astringent diet (low in insoluble fiber and fat, free of lactose, irritating or flatulent foods).
Only patients with watery stools received loperamide at baseline until the consistency improved
to mushy.
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2.2. Study Population
Patients were included according to the following criteria: adult patients with confirmed diagnosis
of cancer, receiving cancer therapy (antitarget therapy, chemotherapy, radiotherapy, or chemotherapy
and radiotherapy), and with malnourishment or at risk of malnourishment associated with OTRD.
Patients were excluded from the study when they did not provide written informed consent,
their life expectancy was <3 months, diarrhea was secondary to the treatment with antibiotics,
H2-receptor antagonists or prokinetics, laxatives or osmotically active agents, patients with Clostridium
difficile infection, and with any concomitant gastrointestinal disorder not associated with the tumor or
cancer treatment.
2.3. Study Outcomes
This study aimed to assess the effectiveness of the proposed OEN protocol in improving the
nutritional status and stool frequency and consistency in patients with OTRD.
The nutritional status was assessed at baseline and following 8 weeks of OEN treatment through
the SGA [15]. The SGA is a nutritional assessment method that considers body weight, body mass
index (BMI), dietary intake, gastrointestinal symptoms, physical examination (loss of subcutaneous fat,
muscle wasting, etc.), muscular function, and albumin levels. Patients were classified as: (1) at risk of
malnourishment, (2) moderate malnourished or (3) severe malnourished. Based on inclusion criteria,
all the patients included had some level of malnourishment, and none was well-nourished, being the
category “at risk of malnutrition” the best possible clinical status in these patients. We defined that
the protocol was effective when: (1) the nutritional status was maintained at risk of malnourishment,
(2) improved from moderate to at risk of malnourishment or from severe to moderate malnourishment
(1-level improvement), or (3) improved from severe to at risk of malnourishment (2-level improvement).
Worsening of nutritional status was considered when: (1) the nutritional status worsened from at risk
to moderate malnourishment or from moderate to severe malnourishment (1-level worsening) or (2)
from low risk to severe malnourishment (2-level worsening).
Stool consistency was evaluated with the Bristol Stool form scale [16] at baseline and after 8 weeks
of OEN treatment. The Bristol Stool form scale classifies the consistency of stools into 7 types; types 1–4
are considered “normal” and types 5 (soft), 6 (mushy) and 7 (watery) indicate diarrhea. The treatment
was considered effective when it (1) allowed the maintenance of normal stools (types 1–4); (2) improved
stool consistency by 1 level (from 7 to 6, 6 to 5, or 5 to 1–4 types), 2 levels (from 7 to 5 or 6 to 1–4 types),
or 3 levels (from 7 to 1–4 types). Conversely, we considered that stool consistency worsened when stool
classification increased by 1 level (from 1–4 to 5, 5 to 6, or 6 to 7 type) or 2 levels (from 1–4 to 6 or 5 to 7).
Stool frequency was evaluated by recording the number of stools per day at baseline and after
8 weeks of OEN treatment. Given the wide inter-patient variability, stool frequency was not categorized
and was then expressed as the mean number of stools/day.
Patients reported the average OEN volume consumed throughout the study and compliance was
categorized into the following groups: consumption of all (200 mL/bottle) the OEN content prescribed,
2/3 (150 mL/bottle) of the content prescribed, and 1/2 (100 mL/bottle) of the content prescribed.
Tolerance to the OEN treatment was monitored by recording the frequency 2 h after the OEN intake
of the following events: nausea, vomiting, reflux, abdominal pain, flatulence, satiety, constipation,
or stomach heaviness. Patients rated the frequency of each event as “never”, “rarely”, “sometimes”,
“often”, and “always” after 8 weeks of OEN treatment.
2.4. Statistical Analyses
The statistical package IBM SPSS Statistics v.24.0 (IBM Corp, Armonk, NY, USA) was used for
statistical analysis. Normal distribution of the data was tested with the Kolmogorov–Shapiro–Wilks
test and normality plots. Categorical variables were reported as counts and percentages. Continuous
variables were reported as mean and standard deviations. Differences between periods in categorical
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variables were estimated using the McNemar test. Continuous variables were compared across the
2 periods using paired t-tests. A p < 0.05 was considered statistically significant.
Sample size calculations were performed with the McNemar formula for 2 proportions with
paired data. Considering a nutritional improvement in 20% of the population and, assuming a 5% type
I (α) error, 90% power, and 20% drop out rate, 145 patients were required for this study.
3. Results
3.1. Study Population
A total of 162 patients with OTRD who initiated treatment with OEN were included and
149 completed the study. None of the patients received previous enteral nutrition.Mean ± SD age in
the overall population was 68.6 ± 12.6 years, and 55% were men. The tumor was localized in 52.9%
of cases, and 50.4% of patients received curative treatment, and chemotherapy + radiotherapy was
the treatment of choice in 46.3% of cases (Table 1). No patient required a reduction in cancer therapy
throughout the study.
Table 1. Demographic and clinical characteristics of study participants.
n = 149
Age (years), Mean (SD) 68.6 (12.6)




Weight (kg), Mean (SD) 62.9 (12.1)
BMI (kg/m2), Mean (SD) 22.6 (3.9)
Resectability (* n = 136)
Unresectable 64 (47.1%)
Localized 72 (52.9%)


















* number of patients with available data. % are calculated over the patients with available data. BMI, Body Mass
Index. Demographic and clinical characteristics were not significantly different by sex, except for the proportion of
specific types of tumors (such as gynecologic).
3.2. Nutritional Status
The nutritional status at baseline assessed with the SGA showed that 34.9% of patients were at risk
of malnourishment (lowest level of malnourishment), 54.4% were moderately malnourished, and 10.7%
severely malnourished. After 8 of weeks of nutritional support with OEN, the proportion of patients
at risk of malnourishment increased (62.2%) while that of moderately and severely malnourished
decreased (34.5% and 3.4%, respectively). The changes in the nutritional status from baseline to week 8
were statistically significant (p < 0.001). This resulted in an improvement in the nutritional status in
Nutrients 2020, 12, 1534 5 of 14
48.3% of patients and a worsening in 14.1% of patients. Taken together, OEN support was effective
in 68.5% of cases: 48.3% improved the nutritional status, and 20.1% were maintained at low risk of
malnourishment (the best possible status in these patients) (Figure 1).
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Figure 1. Change in nutritional status after 8 weeks of oligomeric enteral nutrition (OEN). The bars
show the proportion of patients at risk of malnourishment and with moderate or severe malnourishment
at baseline and after 8 weeks of OEN tr atment. The change in the nutritional status from baseline to
week 8 was statistically sign ficant (p < 0.001). The table shows the changes in th nutritional status
(improve t nd worseni g) nd the effectiveness of the OEN algorithm in improving the nutritional
status. Patient’s nutritional status wa classified as: (1) at risk of malnourishment, (2) moderate
malnourishment, or (3) s vere malnourishment.
The nutritional status significantly improved in all patient subgroups regardless of the type of
tumor, type of treatment, treatment modality, resectability, and whether they received targeted therapy
or cytotoxic treatment (Figure S1).
BMI was significantly higher following 8 weeks of OEN treatment compared to baseline (22.93 vs.
22.64 kg/m2; p = 0.004) (Figure 2). Serum albumin (g/dL) levels were 2.88 g/dL at baseline and
significantly increased with the OEN protocol after 8 weeks (3.45 g/dL; p < 0.001) (Figure 2). Differences in
the change in BMI did not reach statistical significance for patients receiving radiotherapy, radiotherapy
+ chemotherapy, targeted therapies, or non-cytotoxic therapy. The change in albumin levels was
statistically significant for all the patient subgroups.
3.3. Stool Consistency and Frequency
Stool consistency significantly changed with the 8-week OEN protocol (p < 0.001). The proportion
of patients with normal and soft stools increased (from 14.1% to 33.6% and from 21.5% to 37.6%), whereas
mushy and watery stools decreased (from 38.3% to 26.8% and from 26.2 to 2%) (Figure 3). Changes in
stool consistency from baseline to week 8 were statistically significant (p < 0.001). After 8 weeks of
nutritional support with OEN, 57.7% of patients changed the stool consistency, with 24.2% and 24.8%
showing 1- and 2-level improvement, respectively. The treatment showed a 71.1% effectiveness in
improving stool consistency (13.4% maintained stool types 1–4 and 57.7% improved stool consistency).
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Stool consistency was significantly better after 8 weeks of OEN treatment in all stratification groups,
except for the subgroups of patients receiving targeted therapy or non-cytotoxic treatment.
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Figure 3. Change in stool consistency after 8 weeks of oligomeric enteral nutrition (OEN). The bars
show the proportion of normal, soft, mushy, and watery stools at baseline and after 8 weeks of OEN
treatment. Changes in stool consistency from baseline to week 8 were statistically significant (p < 0.001).
The table shows the proportion of patients with changes in stool consistency and the effectiveness of
the OEN protocol in improving stool consistency.
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The mean number of stools per day decreased from baseline (4.17 ± 3.33 stools/day) to week 8
(1.42 ± 1.63 stools/day; p = 0.0041) (Figure 4). Stool frequency significantly improved in all stratification
groups with the exception of patients that received targeted therapy.
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3.4. Patients with Persistent Diarrhe
We next analyzed the subgroup of patients for whom the presence of diarrhea did not improve
with the OEN protocol. Despite not improving the consistency or frequency of stools, we observed
a significant improvement in the nutritional status (p = 0.04) and albumin levels (p = 0.009) in those
patients with persist nt diarrhea. Of note, 46% of patients improv d the nutritional status (40% by
1 level and 6% by 2 levels). In hose patients with persistent diarrhea, th utritional tatus worsened
in 16% of patients and was maintained i 38% (with 12% of patients at risk of malnourishmen and
26% with moderate malnou ishment) (Figure 5).
3.5. Compliance
72.3% of patients reported consuming the total content of OEN prescribed, 20.9% 2/3 of the content
prescribed and 6.8% 12 of the content prescribed throughout the study. Nutritional support with OEN
was associated with good tolerability in 80.3% of patients and with moderate intolerance in 19.7% of
patients (Table 2).
Table 2. Compliance and tolerance to oligomeric enteral nutrition (OEN) after 8 weeks of treatment.
Treatment Compliance (* n = 148)
Total content prescribed 107 (72.3%)
2/3 bottle content prescribed 31 (20.9%)
1/2 bottle content prescribed 10 (6.8%)
Treatment tolerance (*n = 147)
Good tolerance 118 (80.3%)
Moderate intolerance 29 (19.7%)
Severe intolerance 0 (0.0%)
* Number of patients with available data. % are calculated over the patients with available data.
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Figure 5. Nutritional status evolution in those 50 patients who did not improve diarrhea after
8 weeks of oligomeric enteral nutrition (OEN). The graph shows the proportion of patients at risk of
malnourishment, with moderate or severe malnourishment at baseline and after 8 weeks of nutritional
support with OEN. The table shows the proportion of patients with changes in the nutritional
status and the effectiveness of the OEN protocol in improving the nutritional status in patients with
persistent diarrhea.
When analyzing compliance rates in different patient subgroups, we observed that compliance
rates were significantly higher after 8 weeks of OEN treatment relative to baseline in all subgroups.
Nevertheless, we found poorer compliance rates in patients under palliative vs. curative care and
with unresectable vs. localized tumors. Regarding the modality of cancer treatment, compliance was
lower in patients receiving chemotherapy vs. radiotherapy or both, targeted vs. non-targeted therapy,
or cytotoxic vs. non-cytotoxic treatment.
The majority of patients rated the frequency of different symptoms as “never” or “rarely” present.
Regarding potential symptoms associated with OEN treatment, the reported absence of symptoms
was the following: no nausea in 82.3% of patients, no vomiting in 88.4% of patients, no reflux in 78.2%
of patients, no flatulence in 69.2% of patients, no abdominal pain in 77.8% of patients, no satiety in
51.7% of patients, no constipation in 91.2% of patients, and no heaviness in 68% of patients (Figure S2).
4. Discussion
This study showed that the proposed OEN algorithm seemed effective in improving the nutritional
status, frequency and consistency of stools and was associated with high compliance rates in patients
with OTRD.
Unlike previous studies, we included 149 oncologic patients with several types of tumors and
receiving different cancer treatment modalities. The overall analysis of patients allowed us to assess
the general response to OEN in OTRD patients, whereas patient subgroups were useful for assessing
specific responses. In the overall population, mean age was 68.6 years, most of the patients included
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were at risk of malnourishment or moderately malnourished (88.4%), and the most common tumor
type was colon.
An important finding of our study is the improvement in the nutritional status observed in 48.3%
of patients and the effectiveness of the treatment (68.5%). We observed an increase in the proportion of
patients at risk of malnourishment and a decrease in those with moderate/severe malnourishment in
the overall population and in different patient subgroups in our study. Unlike other studies using the
turnover rate of plasma proteins (prealbumin, transferrin, and retinol-binding protein) and changes in
body weight as indicators of nutritional status, this study comprehensively assessed the nutritional
status of patients through the SGA, BMI change, and albumin levels. Indeed, to our knowledge,
none of the studies using elemental diet in cancer patients used the SGA to assess the nutritional status,
despite the fact that it is considered the recommended nutritional assessment test for cancer patients.
The randomized controlled trial comparing the efficacy of oligomeric vs. polymeric formulas used
the Prognostic Nutritional Index (PNI) and the Controlling Nutritional Status (CONUT) and showed
significantly better scores for the CONUT in patients receiving the oligomeric formula [17]. Most of
the studies using elemental diet formulations reported no significant differences in the nutritional
status between intervention and control groups in cancer patients [18–21]. In contrast, in one study
the elemental diet improved the intestinal mucosal inflammation and nutritional status of patients
with Crohn’s Disease [14]. However, it is important to note that previous results were based on
well-nourished patients at baseline, and in our study, all the patients included had certain level
of malnourishment.
In line with the improvement in nutritional status revealed by the SGA, serum albumin levels
significantly increased from 2.88 to 3.45 g/dL upon treatment with OEN. A previous study reported
a decrease in albumin after 4 weeks of Elental® nutritional support (80 g/300 kcal amino-acid-rich,
fat free, elemental diet) [22], while in other study the changes were minimal and non-significant after
6 months of either oligomeric or polymeric formula [17] or 14 days of microbial immune nutrition [23].
OEN was also associated in our study with a significant increase in BMI after 8 weeks. Previous
results reporting the effect of nutritional support on BMI have been heterogeneous. The effect of
Elental® on body weight was inconsistent, with one randomized study reporting a significant
difference in body weight change when compared with the control group in patients who received
adjuvant chemotherapy for gastric cancer [24], other study showing a preservation of lean body
mass after 4 weeks of nutritional support during chemo- or chemoradiotherapy in patients with
esophageal cancer [22], and two studies showing no differences in patients with oral squamous cell
carcinoma [18,19]. Furthermore, Ohkura et al. found no significant differences in the change in body
weight between oligomeric and polymeric formulas after esophagectomy [17]. The importance of body
weight improvement is derived from the association between this variable and negative quality of
life and worse long-term prognosis [25] and also considering that severe weight loss (>10%) has been
acknowledged as a risk factor for non-relapse mortality [26].
The OEN protocol was effective in improving stool consistency, with 57.7% of patients showing
an improvement, and a remarkable reduction in the proportion of watery stools (from 25.5% to 2%).
These improvements resulted in the OEN treatment being effective for stool consistency in 71.1%
of cases. In analyzing these results, it is important to consider that patients with watery stools at
baseline received loperamide until changing the consistency to mushy. Although the use of this
antidiarrheal drug contributed to improving the consistency in those patients, its use in only 26.2% of
patients does not fully explain the improvement in stool consistency observed in the overall population
(57.7%). Likewise, the reduction in stool frequency from 4.17 stools/day at baseline to 1.42 stools/day
after 8 weeks was also striking. Regarding cancer therapy modality, the higher stool frequency per
day at baseline was observed in patients receiving chemotherapy and radiotherapy (5.46 stools/day)
as previously reported [8], although this subgroup also experienced the highest decrease in stool
frequency after OEN (reduction of −4.13 stools/day). In this context, it is interesting to note that
the subgroup of patients receiving both chemotherapy and radiotherapy also showed the highest
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compliance. Regarding previously reported effects of enteral nutrition on diarrhea, a study found that
the frequency of diarrhea was significantly lower with an oligomeric vs. a polymeric formula [17],
and two showed a higher incidence of diarrhea in the elemental diet group as compared with the
control group [27] or azulene oral rinse [22].
A relevant finding of this study is that the OEN support seemed effective in improving the
nutritional status even in those patients with persistent diarrhea despite the OEN protocol. This result
is of remarkable interest since it implies that patients could benefit from this OEN protocol, despite the
fact that they do not notice substantial changes in the frequency and consistency of stools.
Patients reported high compliance rates with the OEN support, with 72.3% reporting ingesting
the total content prescribed. The high compliance rates observed are in line with the good tolerability
(80.3%) associated with this nutritional support. Importantly, common symptoms responsible for
enteral nutrition interruptions [12], such as nausea or vomiting, were seldom present in our study.
Satiety, heaviness and flatulence were the symptoms with a higher incidence, although still in >80% of
cases were “never” or “rarely” reported. These results are of particular importance, as poor tolerability
and palatability of oral nutritional formulas, together with tolerability symptoms associated with
cancer treatment, are the main barriers to treatment compliance that lead to suboptimal effectiveness
of nutritional supports [28]. Previous studies provided heterogeneous results regarding treatment
compliance. In patients receiving chemotherapy and Elental® formula as elemental diet, a compliance
rate of 71.4% was reported for patients with gastric cancer [24] and of 70% in patients with esophageal
cancer [29]. Poorer compliance rates were observed in patients undergoing pelvic radiotherapy
and partial replacement with oral E028, showing a median overall daily intake of 21% of caloric
requirements [21].
Taken together, we observed that OEN seemed to serve its first purpose of improving the
nutritional status of patients. One of the main contributors to this effectiveness could be the compliance
with the treatment that allows the optimal effect of this nutritional support. Treatment compliance,
in turn, is likely influenced by the improvement in health status (nutritional, body weight, frequency of
stools), which further encourages patients to remain compliant. The improved nutritional status is also
probably reflecting the higher digestibility of a peptide-based formulation, which has the potential to
maintain the gastrointestinal mucosa integrity and facilitate nutrient absorption [29]. Furthermore,
oligomeric formulas have been associated with reduced mucosal production of pro-inflammatory
cytokines [14] and pancreatic or biliary stimulation [30]. It is important to highlight that we cannot
directly compare our results with those using elemental supplements previously published given
their different methodological design [13]. First, most of the studies included a limited number of
patients [22,29,31]. Second, the nutritional doses provided were different (in most of the studies
patients received 300 Kcal and 14.1 g/protein/day and, in our study, patients received between 400 Kcal
and 18.6 g/protein/day and 600 Kcal and 27.9 g/protein/day) [18,29,32]. Third, the follow-up period of
these studies was relatively short for achieving nutritional changes [21,22]. Fourth, none of the studies
primarily aimed to assess the impact of nutritional supports on the nutritional status and, in several of
them, this was neither a secondary endpoint [31]. Fifth, when reported, patients were well-nourished
at baseline, so better results are expected in patients with certain level of malnourishment as in our
study [18,19,22,24].
There are different limitations associated with this study that are worth mentioning. First, the lack
of control group does not allow to rule out that factors, other than the OEN protocol, could have
conditioned the results obtained. Potential factors could be following an astringent diet in all patients,
the use of transient antidiarrheal drugs in patients with watery stools until changing the consistency to
mushy, or the evolution of diarrhea itself. Further investigations with a controlled design are needed to
confirm our results. However, as this is the first study following the proposed OEN protocol in clinical
practice, our study was not intended to compare the effectiveness of this protocol with other nutritional
support but to test whether the protocol help improve the nutritional status. In this regard, since this
observational study included patients with nutritional deficit for whom the absence of nutritional
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support could have compromised their status, the use of placebo was not considered. Moreover,
as previous animal studies reported reduced pancreatic or biliary stimulation with oligomeric vs.
polymeric diet [30] and a lower frequency of diarrhea and improved nutritional status was observed
with a oligomeric vs. a polymeric formula [17], we did not consider comparing the effectiveness of our
OEN protocol with a polymeric formula. Second, the inclusion of patients did not follow selective
inclusion criteria. Although this allowed us to obtain comprehensive information among a wide
range of clinical groups, the sample size in some subgroups was not powered to establish reliable
conclusions. Third, the duration of follow up was relatively short to capture long term differences.
Fourth, we cannot directly compare the compliance rates obtained in our study with those previously
observed, as patients reported the total volume ingested throughout the study and other studies
were based on the doses recorded in the patient diary. Fifth, antidiarrheal drugs were used only in
patients with watery stools until the consistency improved to mushy. As the proportion of patients who
reported watery stools at baseline was 26.2%, the use of loperamide does not completely explain the
improvement in the frequency and consistency of stools observed in the overall population. Although
loperamide undoubtedly contributed to improving the consistency of stools, we observe this effect
also in patients not treated with this antidiarrheal drug (soft or mushy stools consistency, 59.8% of
patients). Finally, due to the observational design of our study, we cannot ensure that the clinical
benefits observed are fully due to the OEN protocol.
In contrast, this study is one of the first comprehensively describing the effectiveness of an OEN
protocol targeting both the nutritional status of patients and the evolution of OTRD. Our study included
a considerable sample size, which is larger than that in most of the studies published to date and
assessed the nutritional status with a valid and reliable tool [33,34] and with other nutritional indicators
(albumin, BMI). To our knowledge, this study is the first in assessing the change in nutritional status
with an OEN protocol in patients with different types of tumors. Moreover, most of the previous studies
were conducted in Japan [17–20,22,24,27,29,31], and the present study provides valuable information
for patients in Europe.
5. Conclusions
The OEN protocol proposed in this study seemed effective in improving patient’s nutritional
status, stool frequency, and consistency with high rates of compliance in patients with OTRD.
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